Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery

References

• Adi H, Young PM, Chan H-K, Stewart P, Agus H, Traini D. Co-spray dried antibiotics for dry powder lung delivery. J Pharm Sci 2008; 97: 3356–66
   PubMed Web of Science ®Google Scholar
• Arppe J, Vidgren M, Waldrep JC. Pulmonary pharmacokinetics of cyclosporine A liposomes. Int J Pharm 1998; 161: 205–14
   Web of Science ®Google Scholar
• Arunothayanun P, Turton JA, Uchegbu IF, Florence AT. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes. J Pharm Sci 1999; 88: 34–7
   PubMed Web of Science ®Google Scholar
• Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. Am J Med 1989; 87: S123–7
   PubMed Web of Science ®Google Scholar
• Bozeman L, Burman W, Metchock B, Welch L, Weiner M. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386–91
   PubMed Web of Science ®Google Scholar
• Brown AE, Smith G. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. Am J Med 1989; 87: S266–8
   Google Scholar
• Bush A. Decisions facing the cystic fibrosis clinician at first isolation of Pseudomonas aeruginosa. Paediatr Respir Rev 2002; 3: 82–8
   PubMedGoogle Scholar
• Cavallo J, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002; 46: 2307–19
   PubMed Web of Science ®Google Scholar
• Cheung DOY, Halsey K, Speert DP. Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun 2000; 68: 4585–92
   PubMed Web of Science ®Google Scholar
• Chougule MB, Padhi BK, Misra A. Nano-liposomal dry powder inhaler of amiloride hydrochloride. J Nanosci Nanothechnol 2006; 9: 1–9
   Google Scholar
• Conley J, Yang H, Wilson T, Blasetti K, Ninno VD, Schnell G. Aerosol delivery of liposome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997; 41: 1288–99
   PubMed Web of Science ®Google Scholar
• Conway S, Brownlee K, Denton M, Peckham D. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003; 2: 321–32
   PubMedGoogle Scholar
• Desai TR, Finlay WH. Nebulization of niosomal all-trans-retinoic acid: An inexpensive alternative to conventional liposomes. Int J Pharm 2002; 241: 311–7
   PubMed Web of Science ®Google Scholar
• Easmon CCF, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother 1985; 16: 67–73
   PubMed Web of Science ®Google Scholar
• Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm 2001; 219: 61–72
   PubMed Web of Science ®Google Scholar
• Fenske DB, Cullis PR. Encapsulation of drugs within liposomes by pH-gradient techniques. Liposome Technology: Entrapment of Drugs and Other Materials into Liposomes, G Gregoriadis. Informa Healthcare, New York 2007; 2: 27–50
   Google Scholar
• Finlay WH, Wong JP. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int J Pharm 1998; 167: 121–7
   Web of Science ®Google Scholar
• Geller D, Rosenfeld M, Waltz D, Wilmott R. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003; 123: 28–36
   PubMed Web of Science ®Google Scholar
• Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm 2008; 357: 286–94
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Lu D, Ashley ED, Stout J. Inhaled azithromycin therapy. J Aerosol Med 2006; 19: 54–60
   PubMedGoogle Scholar
• Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113: 9–14
   PubMed Web of Science ®Google Scholar
• Hwang SH, Maitani Y, Qi XR, Takayama K, Nagai T. Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods. Int J Pharm 1999; 179: 85–95
   PubMed Web of Science ®Google Scholar
• Joshi M, Misra A. Dry powder inhalation of liposomal ketotifen fumarate: Formulation and characterization. Int J Pharm 2001a; 223: 15–27
   PubMed Web of Science ®Google Scholar
• Joshi M, Misra A. Liposomal budesonide for dry powder inhaler: Preparation and stabilization. AAPS Pharm Sci Technol 2001b; 4: 1–10
   Google Scholar
• Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W. Iloprost-containing liosomes for aerosole application in pulmonary arterial hypertension: Formulation aspects and stability. Pharm Res 2007; 24: 277–87
   PubMed Web of Science ®Google Scholar
• Lai H, Cheng Y, Cho H, Kosorok M, Farrell P. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol 2004; 159: 537–46
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Chauhan S, Lawrence SM, Barlow DJ. The formation, characterisation and stability of nonionic surfactant vesicles. STP Pharm Sci 1996; 6: 49–60
   Google Scholar
• Li Z, Zhang Y, Wurtz W, Lee JK, Malinin VS, Durwas-Krishnan S, Meers P, Perkins W. Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008; 21(3)245–53
   PubMed Web of Science ®Google Scholar
• Liu T, Guo R. Investigation of PEG 6000/Tween 80/Span 80/H2O niosome microstructure. Colloid Polym Sci 2007; 285: 711–3
   Web of Science ®Google Scholar
• LoBue PA. Inhaled tobramycin not just for cystic fibrosis anymore?. Chest 2005; 127: 1098–101
   PubMed Web of Science ®Google Scholar
• Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins R. Biofilm penetration triggered release and in vivo activity of inhaled liposomal amikacin in chronic pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008; 61: 859–68
   PubMed Web of Science ®Google Scholar
• Mugabe C, Azghani AO, Omri A. Liposome-mediated gentamicin delivery: Development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2005; 55: 269–71
   PubMed Web of Science ®Google Scholar
• Mugabe C, Halwani M, Azghani AO, Lafrenie RM, Omri A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 2016–22
   PubMed Web of Science ®Google Scholar
• Newman SP. Principles of metered-dose inhaler design. Respir Care 2005; 50(91)177–90
   Google Scholar
• Niven RW. Feasibility studies with recombinant human granulocyte colony-stimulating factor. Inhalation Delivery of Therapeutic Peptides and Proteins, AL Adjei, PK Gopta. Marcel Dekker, New York 1997; 412–54
   Google Scholar
• Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular maycobacterium avium infection. Antimicrob Agents Chemother 1995; 39: 2104–11
   PubMed Web of Science ®Google Scholar
• Omri A, Suntres EZ, Pang NS. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Int J Antimicrob Agents 2002; 64: 1407–13
   Google Scholar
• Pardakhty A, Varshosaz J, Najafabadi AR. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 2007; 328: 130–41
   PubMed Web of Science ®Google Scholar
• Parthasarathi G, Udupa N, Umadevi P, Pillai GK. Niosome encapsulated of vincristine sulfate-improved anticancer activity with reduced toxicity in mice. J Drug Target 1994; 2: 173–82
   PubMed Web of Science ®Google Scholar
• Seras-Cansel A, Ollivon M, Lesieur S. Generation of non-ionic monoalkyl amphiphile-cholesterol vesicles: Evidence of membranen impermeabilityto octyl glycoside. STP Pharm Sci 1996; 6: 12–20
   Google Scholar
• Steward J, Piercy T, Lever MS, Simpson AJH, Brooks TJG. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int J Antimicrob Agents 2006; 27: 439–43
   PubMed Web of Science ®Google Scholar
• Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005; 305: 180–5
   PubMed Web of Science ®Google Scholar
• Tomlin K, Clark S, Ceri H. Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex. J Microbiol Methods 2004; 57: 95–106
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33–70
   Web of Science ®Google Scholar
• Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv 2003; 10: 251–62
   PubMed Web of Science ®Google Scholar
• Vervaet C, Byron PB. Drug–surfactant–propellant interactions in HFA-formulations. Int J Pharm 1999; 186: 13–30
   PubMed Web of Science ®Google Scholar
• Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Dosing of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004; 269: 37–49
   PubMed Web of Science ®Google Scholar
• Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Release 2003; 92: 256–73
   Web of Science ®Google Scholar
• Yoshioka T, Strenberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan riester (Span 85). Int J Pharm 1994; 105: 1–6
   Web of Science ®Google Scholar